EPRX Stock Chart & Stats
$7.43
$0.31(5.34%)
At close: 4:00 PM EDT
$7.43
$0.31(5.34%)
Day’s Range― - ―
52-Week Range$5.25 - $9.32
Previous CloseN/A
Volume182.59K
Average Volume (3M)813.48K
Market Cap
$495.68M
Enterprise Value$469.12M
Total Cash (Recent Filing)$133.44M
Total Debt (Recent Filing)$1.84M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding65,906,630
10 Day Avg. Volume1,386,774
30 Day Avg. Volume813,483
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.31K
Enterprise Value/Ebitda-8.41
Forecast
1Y Price Target
$17.00Price Target Upside128.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformA proprietary delivery platform may provide a differentiated foundation for developing multiple therapies with sustained local activity. If clinical and regulatory objectives are achieved, this technology could support repeatable product development and broader commercial opportunities across inflammatory indications.
Low Financial LeverageVery low leverage gives Eupraxia greater financial flexibility than a highly debt-funded development company. The equity base provides capacity to support clinical programs without substantial interest obligations, although future funding remains important because operations are not yet self-financing.
Multi-Indication PipelineA pipeline spanning multiple inflammatory indications creates opportunities to apply the company’s delivery approach across more than one potential market. Broader clinical applications can diversify development outcomes and increase the platform’s potential strategic value if candidates demonstrate efficacy and safety.
Bears Say
Pre-Revenue Business ModelThe absence of commercial revenue means Eupraxia currently lacks an operating revenue engine to fund research, development, and corporate costs. Its ability to create value therefore depends on successful clinical progress, regulatory approval, and eventual commercialization or licensing.
Widening Net LossesLosses have widened materially over successive periods, indicating that spending is increasing before any product revenue is available. Persistent and accelerating losses can erode the equity base over time and raise the amount of external capital needed to advance the pipeline.
Increasing Cash BurnNegative operating and free cash flow show that reported losses are translating into substantial cash outflows rather than mainly non-cash accounting charges. Continued burn increases reliance on financing and can constrain development plans if access to new capital becomes less favorable.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $5.25 and its highest was $9.32 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is $495.68M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 30 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported -$0.221 earnings per share for the quarter, beating the consensus estimate of -$0.224 by $0.003.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.27.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 65,906,630 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.221 in its last earnings report, beating expectations of -$0.224. Following the earnings report the stock price went down -3.284%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (128.80% Upside)
$17.00 (128.80% Upside)
Blogger Sentiment
Bullish
EPRX Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth $150.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 17.8%
Last 30 Days ▲ 17.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.60%
12-Months-Change
Fundamentals
Return on Equity
-45.29%
Trailing 12-Months
Asset Growth
516.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
EPRX Stock 12 Month Forecast
Average Price Target
$17.00
▲(128.80% Upside)
Technical Analysis
Ownership Overview
10.21% Insiders
0.03% Mutual Funds
26.14% Other Institutional Investors
63.40% Public Companies and
Individual Investors